Stabilizing the volume of exudative fluid, including subretinal fluid, may help maximize anti-VEGF treatment outcomes for patients with nAMD.
Standard treatment for nAMD involves repeated anti-VEGF injections. A recent study has found that an investigational therapy, administered through a bioerodible insert in the vitreous cavity, reduced treatment burden by 74% in one year.
Faricimab, a new drug for nAMD, offers patients similar benefits at 16-week intervals as aflibercept at eight-week intervals, a study shows.
Patients with diabetic eye disease or vein occlusion lost more vision than patients with age-related macular degeneration when they missed an intravitreal injection during the COVID-19 shutdown.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A lapse in anti-VEGF therapy can cause an irreversible decrease in visual acuity in neovascular age-related macular degeneration.
HAWK and HARRIER results show that brolucizumab delivers a superior retinal drying effect compared with aflibercept for patients with neovascular age-related macular degeneration.